The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...
Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...
Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the ...
The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...
Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.